ClinicalTrials.gg
CompletedNCT04849845DOSUpdated Sep 18, 2023Results posted

Afrezza® Dosing Optimization Study

A Phase 4 interventional study of Afrezza Dose 1 and Afrezza Dose 2 in Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Mannkind Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Mannkind Corporation.

Enrollment
15th of 18
20 · median 34
Started
2021
with 1 other
Phase 4
3 of 21
none open now
Registered
17th of 21
by date

Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 17th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, or all of them as a file.
02

Study summary

MKC-TI-191 is a Phase 4, single-arm, multicenter, proof-of-concept clinical trial evaluating the efficacy and safety of Afrezza, administered according to the current Afrezza prescribing information (PI) compared to a titrated dose, in combination with a basal insulin in adult subjects (≥18 years of age) with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Eligible subjects will be on a stable regimen consisting of a basal bolus insulin therapy prior to screening. The study is composed of up to 4 clinic visits (screening, 2 treatment visits, and a follow-up visit). Two individual doses of Afrezza will be administered during a meal challenge at Visits 2 and 3. The duration of each subject's participation in the trial is expected to be approximately 2 weeks.

Read the detailed description

Screening (Visit 1): Informed consent and California Experimental Subjects Bill of Rights will be signed and eligibility confirmed. Eligible subjects will be enrolled at Visit 1.

Subjects will come into the clinic in a fasting state for a meal challenge and individual dose of Afrezza during Visits 2 and 3. At the beginning of each visit, before their dose of Afrezza, subjects will have FEV1 measurements taken in the clinic. Each meal challenge will consist of 1 to 2 bottles of nutritional shake to be fully consumed within 15 minutes. The nutritional shake will contain approximately 240 calories, 41 g carbohydrate, 10 g protein, and 4 g fat per bottle. Each Afrezza dose will be administered at the start of the meal challenge.

Visit 2: The first dose of Afrezza will be based on the dose of subcutaneous (SC) rapid-acting analogue (RAA) insulin that the subject would normally take, converted according to the guidelines provided in the current Afrezza prescribing information. If subject's normal RAA dose is \<4 units or 5 units, subject will be asked to consume enough nutritional shake, per their normal I:C ratio, to cover an RAA dose of 4 units or ≥6 units such that their Afrezza dose at Visit 3 is higher than the dose taken at Visit 2. After completing the standardized meal challenge, the Investigator will decide, based on the subject's glucose excursion at Visit 2, if the subject should proceed to Visit 3 where a second dose of Afrezza will be administered.

Visit 3: The second dose of Afrezza will be based on the dose of SC RAA that the subject would normally take, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.

Follow-up Visit (Visit 4): Subjects will return for safety assessments, including a final FEV1 measurement, 24 to 72 hours after their last dose of Afrezza.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Keywords

  • Afrezza
  • Dosing
  • Technosphere
  • Inhaled
  • Insulin
  • Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Subjects will be asked to provide a recent negative COVID-19 test (if available), confirm they have no symptoms of COVID-19, or provide evidence of COVID-19 vaccination.

Inclusion criteria

Inclusion Criteria:

  1. Subjects ≥18 years of age at the time of signing the form
  2. Clinical diagnosis of T1DM or T2DM (per the Investigator) and on a stable basal-bolus insulin regimen

Exclusion criteria

Exclusion Criteria:

  1. History of asthma, , or any other pulmonary disease (e.g., cystic fibrosis, bronchopulmonary dysplasia), use of any medications to treat such conditions within the last year, or significant congenital or acquired cardiopulmonary disease
  2. History of serious complications of diabetes (e.g., active proliferative retinopathy or symptomatic autonomic neuropathy)
  3. On dialysis
  4. Respiratory tract infection within 14 days before screening (subject may return 14 days after resolution of symptoms for rescreening)
  5. Treatment with any drug in the past 30 days or an investigational device in the past 2 weeks
  6. Any disease other than diabetes or initiation of any new medication that, in the judgment of the Investigator, could have a direct impact on glycemic control during the study
  7. Use of antiadrenergic drugs (e.g., beta blockers and clonidine)
  8. Any concurrent illness (other than diabetes mellitus) not controlled by a stable therapeutic regimen
  9. History of a significant eating disorder (e.g., anorexia or bulimia nervosa)
  10. Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the Investigator or the Sponsor, would make the subject an unsuitable candidate for participation in the study
  11. History of smoking (includes cigarettes, cigars, pipes, vaping devices, and marijuana) in the 6 months before screening
  12. Female subject who is pregnant, breastfeeding, intends to become pregnant, or is of and not using adequate methods as required by local regulation or practice (may include sexual abstinence)
  13. An event of severe hypoglycemia, as judged by the Investigator, within the 90 days before screening
  14. An episode of diabetic ketoacidosis (DKA) requiring hospitalization within the 90 days before screening
  15. Exposure to Afrezza in the 30 days before screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Afrezza

    The test product is defined as Afrezza \[insulin human\] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.

    Combination Product: Afrezza Dose 1 · Combination Product: Afrezza Dose 2

Interventions

  • Combination productAfrezza Dose 1

    The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.

  • Combination productAfrezza Dose 2

    The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.

06

What researchers measure

Primary outcomes

  1. Post-prandial Glucose Excursion

    Mean glucose change from baseline (or postprandial glucose excursion \[PPGE\]) based on self-monitored blood glucose (SMBG) at 15, 30, 45, 60, 90 and 120 minutes after the dose of Afrezza with baseline defined as SMBG at the time of the dose of Afrezza (t=0)

    Time frame: 120 minutes post-dose

Secondary outcomes

  1. Number of Subjects With at Least 1 Event of Level 1 Hypoglycemia

    Number of subjects with at least 1 event (also referred to as incidence) of Level 1 hypoglycemia (\<70mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.

    Time frame: 120 minutes

  2. Percent of Level 1 Hypoglycemia

    Percent of total SMBG measurements \<70 mg/dL (Level 1 hypoglycemia) within the 120 minutes after Afrezza dosing.

    Time frame: 120 minutes

  3. Number of Subjects With at Least 1 Event of Level 2 Hypoglycemia

    Number of subjects with at least 1 event (also referred to as incidence) of Level 2 hypoglycemia (\<54mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.

    Time frame: 120 minutes

  4. Percent of Level 2 Hypoglycemia

    Percent of total SMBG measurements \<54 mg/dL (Level 2 hypoglycemia) within the 120 minutes after Afrezza dosing

    Time frame: 120 minutes

  5. Number of Subjects With At Least 1 Event of Severe Hypoglycemia

    Number of subjects with at least 1 event (also referred to as incidence) of severe hypoglycemia, defined as events requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions within the 120 minutes after Afrezza dosing.

    Time frame: 120 minutes

  6. Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose

    Change in percent predicted forced expiratory volume in 1 second (FEV1) between two points (value at 120 minutes post-Afrezza dose minus value at baseline). Standard deviation was not reported.

    Time frame: 120 minutes post-dose

07

Results

Posted Sep 18, 2023
Limitations and caveats
DOS had no planned or conducted hypothesis testing, and no alpha adjustment was made to account for multiple testing of exploratory endpoints. Instead, DOS aimed to be a small-scale test of the higher dose suggested by previous studies and clinical experience. With no formal hypothesis testing, descriptive statistical comparisons are used to assess the efficacy and safety outcomes of the higher dose for purposes of generating hypothesis for a larger study.

Participant flow

Between April 2021 and May 2021, a total of 20 subjects were enrolled at two investigational sites in the US.

Afrezza Dose 1
Participant flow — Afrezza Dose 1
MilestoneAfrezza
Started20
Completed20
Not completed0
Afrezza Dose 2
Participant flow — Afrezza Dose 2
MilestoneAfrezza
Started20
Completed20
Not completed0

Outcome measures

PrimaryPost-prandial Glucose Excursion

Mean glucose change from baseline (or postprandial glucose excursion \[PPGE\]) based on self-monitored blood glucose (SMBG) at 15, 30, 45, 60, 90 and 120 minutes after the dose of Afrezza with baseline defined as SMBG at the time of the dose of Afrezza (t=0)

Time frame:
120 minutes post-dose
Reported as:
Mean · mg/dL
Post-prandial Glucose Excursion
mg/dLAfrezza Dose 1Afrezza Dose 2
15 minutes PPGE6.8 ± 3.35.6 ± 2.5
30 minutes PPGE25.9 ± 5.721.9 ± 5.6
45 minutes PPGE48.9 ± 6.927.0 ± 6.6
60 minutes PPGE64.2 ± 7.934.3 ± 8.1
90 minutes PPGE82.8 ± 14.336.0 ± 10.2
120 minutes PPGE88.6 ± 17.736.9 ± 13.1
SecondaryNumber of Subjects With at Least 1 Event of Level 1 Hypoglycemia

Number of subjects with at least 1 event (also referred to as incidence) of Level 1 hypoglycemia (\<70mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.

Time frame:
120 minutes
Reported as:
Count of participants · Participants
Number of Subjects With at Least 1 Event of Level 1 Hypoglycemia
ParticipantsAfrezza Dose 1Afrezza Dose 2
Number of Subjects With at Least 1 Event of Level 1 Hypoglycemia01
SecondaryPercent of Level 1 Hypoglycemia

Percent of total SMBG measurements \<70 mg/dL (Level 1 hypoglycemia) within the 120 minutes after Afrezza dosing.

Time frame:
120 minutes
Reported as:
Number · SMBG Measurements
Percent of Level 1 Hypoglycemia
SMBG MeasurementsAfrezza Dose 1Afrezza Dose 2
Percent of Level 1 Hypoglycemia02
SecondaryNumber of Subjects With at Least 1 Event of Level 2 Hypoglycemia

Number of subjects with at least 1 event (also referred to as incidence) of Level 2 hypoglycemia (\<54mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.

Time frame:
120 minutes
Reported as:
Count of participants · Participants
Number of Subjects With at Least 1 Event of Level 2 Hypoglycemia
ParticipantsAfrezza Dose 1Afrezza Dose 2
Number of Subjects With at Least 1 Event of Level 2 Hypoglycemia01
SecondaryPercent of Level 2 Hypoglycemia

Percent of total SMBG measurements \<54 mg/dL (Level 2 hypoglycemia) within the 120 minutes after Afrezza dosing

Time frame:
120 minutes
Reported as:
Number · SMBG Measurements
Percent of Level 2 Hypoglycemia
SMBG MeasurementsAfrezza Dose 1Afrezza Dose 2
Percent of Level 2 Hypoglycemia01
SecondaryNumber of Subjects With At Least 1 Event of Severe Hypoglycemia

Number of subjects with at least 1 event (also referred to as incidence) of severe hypoglycemia, defined as events requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions within the 120 minutes after Afrezza dosing.

Time frame:
120 minutes
Reported as:
Count of participants · Participants
Number of Subjects With At Least 1 Event of Severe Hypoglycemia
ParticipantsAfrezza Dose 1Afrezza Dose 2
Number of Subjects With At Least 1 Event of Severe Hypoglycemia00
SecondaryChange in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose

Change in percent predicted forced expiratory volume in 1 second (FEV1) between two points (value at 120 minutes post-Afrezza dose minus value at baseline). Standard deviation was not reported.

Time frame:
120 minutes post-dose
Reported as:
Mean · change in percent predicted FEV1
Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose
change in percent predicted FEV1Afrezza Dose 1Afrezza Dose 2
Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose0.63 ± 8.25-2.55 ± 5.78

Adverse events

Collected over Duration of the two treatment visits (~8 hours). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afrezza Dose 10/20 (0%)0/20 (0%)1/20 (5%)
Afrezza Dose 20/20 (0%)0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
EventAfrezza Dose 1Afrezza Dose 2
CoughRespiratory, thoracic and mediastinal disorders1/202/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Afrezza
Mean51.2 ± 13.90
Sex: Female, Male
Sex: Female, Male(Participants)Afrezza
Female10
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Afrezza
Hispanic or Latino4
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Afrezza
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)Afrezza
United States20
HbA1c
HbA1c(percentage of Hemoglobin A1c)Afrezza
Mean6.66 ± 0.84
Diabetes type
Diabetes type(Participants)Afrezza
Type 1 diabetes18
Type 2 diabetes2
BMI
BMI(kg/m^2)Afrezza
Mean26.9 ± 6.97
08

Study locations

2 sites
  • AMCR Institute
    Escondido, California 92025, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in May 2021, 1 month.

Results were first posted in Sep 2023, 2 years 3 months after primary completion.

Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
Apr 19, 2021
StartActual
Apr 9, 2021
Primary completionActual
May 28, 2021
CompletionActual
May 28, 2021
Results first posted
Sep 18, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04849845
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Apr 9, 2021
Primary completion
May 28, 2021
Completion
May 28, 2021
Results posted
Sep 18, 2023
Last update
Sep 18, 2023

Study contacts

Kevin Kaiserman, MD
study director · Mannkind Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion